Clivatuzumab MMAE is an ADC consisting of a humanized monoclonal antibody against MUC1 (mucin) and the anti-mitotic cytotoxin MMAE for pancreatic cancer.
Purity:
98.74%
Target:
Antibody-Drug Conjugates (ADCs)|||Mucin
* VAT and and shipping costs not included. Errors and price changes excepted
